<DOC>
	<DOCNO>NCT00420472</DOCNO>
	<brief_summary>This study ass safety , efficacy effect quality life switch kidney transplant patient reduce dose EC-MPS treatment due gastrointestinal problem higher equimolar dose CellCept . Patients switch , initially , EC-MPS ( &lt; 1440g/day ) equimolar dose CellCept , next visit ( day 10 +/- 5 ) CellCept dose increase 250mg/day , daily dose split 3-4 dos . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study CellCept ( Mycophenolate Mofetil ) Kidney Transplant Patients Switched From EC-MPS .</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; first second kidney transplant ; ECMPS therapy &gt; =6 month , stable dose &gt; =2 month ; low recommend dose ECMPS ( &lt; 1440g/day ) due gastrointestinal complaint . patient participate study ; patient currently participate another clinical trial , participate one last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>